

Studies on the Total Synthesis of Formamicin: Synthesis of the C(1)–C(11) Fragment


Noel A. Powell[†] and William R. Roush^{*}

Department of Chemistry, University of Michigan, 930 North University,
Ann Arbor, Michigan 48109

roush@umich.edu

Received December 5, 2000

ABSTRACT



An efficient and highly concise synthesis of **6**, corresponding to the C(1)–C(11) fragment of formamicin (**1**), has been accomplished by a route utilizing a diastereoselective lactate aldol reaction to set the C(6) tertiary ether and the TES–OTf mediated transketalization of the C(6) tertiary methoxymethyl ether and the C(25) PMB ether to set the seven-membered methylene acetal unit (see **37** → **38**).

Formamicin, **1**, was isolated in 1997 from *Saccharothrix* sp. MK27-91F2, an actinomycete strain that was obtained from a soil sample collected at Setagaya-ku, Tokyo, Japan.¹ Besides showing strong activity against phytopathogenic fungi and moderate activity toward Gram-positive bacteria, formamicin displayed very potent cytotoxicity against murine tumor cell lines in vitro, particularly leukemia cells (IC_{50} = 0.13–0.15 ng/mL for EL4, P388, and L1210 leukemia cell lines). Slightly lower cytotoxicity was observed with IMC carcinoma and S180 sarcoma cells (IC_{50} = 0.29 and 3.45 ng/mL, respectively). The structure of **1** was elucidated by mass spectral and high-field 2D NMR techniques, and the absolute configuration was determined through degradation and X-ray crystal analysis.

Formamicin belongs to the plecomacrolide family of macrolide antibiotics that includes the hygrolidins,² conanamycins,³ and bafilomycins.⁴ This natural products family

is noted for the presence of a 16- or 18-membered tetraenic macrolactone ring, a conserved, stereochemically rich C(14)–C(23) propionate segment and a six-membered hemiacetal which is often glycosylated at the C(21) hydroxyl with a 2-deoxy-D-rhamnose unit. Formamicin possesses some unique structural features, including the *n*-pentyl chain at C(25) and a C(6) tertiary alcohol and C(25) secondary alcohol that have been incorporated into a seven-membered methylene acetal.

Our retrosynthetic analysis (Figure 1) calls for formamicin to be assembled from the key fragments **2**,⁵ **3**,⁵ **5**,⁶ and **6**. Fragment **5** is an intermediate in our recently completed total synthesis of bafilomycin A₁.⁶ We report herein a concise synthesis of **6**, corresponding to the C(1)–C(11) fragment of formamicin (**1**).⁷

Our initial efforts to prepare fragment **6** began with the

(3) (a) Kinashi, H.; Someno, K.; Sakaguchi, K.; Higashijima, T.; Miyazawa, T. *Tetrahedron Lett.* **1981**, 22, 3857. (b) Westley, J. W.; Liu, C.-M.; Sello, L. H.; Evans, R. H.; Troupe, N.; Blount, J. F.; Chiu, A. M.; Todaro, L. J.; Miller, P. A. *J. Antibiot.* **1984**, 37, 1738.

(4) Werner, G.; Hagenmaier, H.; Drautz, H.; Baumgartner, A.; Zähler, H. *J. Antibiot.* **1984**, 37, 110.

(5) Roush, W. R.; Bennett, C. E. *J. Am. Chem. Soc.* **1999**, 121, 3541.

(6) Scheidt, K.; Tasaka, A.; Bannister, T. D.; Wendt, M. D.; Roush, W. R. *Angew. Chem., Int. Ed.* **1999**, 38, 1652 and references therein.

(7) References to total syntheses of other members of the plecomacrolide family are provided in Supporting Information.

* To whom correspondence should be addressed.

[†] Present Address: Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105.

(1) (a) Igarashi, M.; Kinoshita, N.; Ikeda, T.; Nakagawa, E.; Hamada, M.; Takeuchi, T. *J. Antibiot.* **1997**, 50, 926. (b) Igarashi, M.; Nakamura, H.; Naganawa, H.; Takeuchi, T. *J. Antibiot.* **1997**, 50, 932.

(2) Seto, H.; Tajima, I.; Akao, H.; Furihata, K.; Otake, N. *J. Antibiot.* **1984**, 37, 610.





Figure 1. Retrosynthetic analysis.

N-acyl oxazolidinone **7** (Scheme 1).⁸ The Bu₂BOTf-mediated asymmetric aldol reaction between **7** and hexanal gave syn-aldol **8** with excellent diastereoselectivity. Following Me₃Al-mediated transamidation of the *N*-acyl oxazolidinone to the corresponding Weinreb amide,⁹ LiAlH₄ reduction of the amide gave diol **9** in good overall yield. The secondary alcohol was selectively protected as a *p*-methoxybenzyl (PMB) ether by formation of the *p*-methoxybenzylidene acetal followed by DIBAL-H reductive cleavage of the less-hindered C–O acetal bond to afford **10** in excellent yield. Swern oxidation¹⁰ of the primary alcohol provided aldehyde **11**, which was used without purification in the following reaction.

We chose to install the C(6) tertiary and C(7) secondary centers via a diastereoselective *O*-alkyl lactate aldol reaction.¹¹ This strategy allows the tertiary center to be introduced as a methoxymethyl (MOM) ether, in a form suitable for subsequent elaboration into the seven-membered acetal of the



natural product. Accordingly, the *Z*(*O*)-lithium enolate^{11b} of the MOM-protected lactate aryl ester **12**¹² was formed by deprotonation with LDA at $-78\text{ }^{\circ}\text{C}$. Addition of aldehyde **11** then gave an 81:19 mixture of aldols **13** and **14** in 91% yield, with the desired all-syn diastereomer **13** predominating.¹³ Although **13** and **14** proved inseparable, LiAlH₄ reduction of the mixture gave the corresponding mixture of diastereomeric diols **15** and **16**, which were easily separable by flash chromatography.

The primary hydroxyl of the major diol isomer **15** was selectively protected as the pivalate ester **17** (Scheme 2). Attempts to protect the remaining secondary alcohol as a TBS ether were disappointing, giving the desired TBS ether in 32% yield along with 52% of recovered diol **17**.

(8) Kamenecka, T. M.; Danishefsky, S. J. *Angew. Chem., Int. Ed. Engl.* **1998**, *37*, 2995.


(9) Nahm, S.; Weinreb, S. M. *Tetrahedron Lett.* **1981**, *22*, 3815.

(10) Mancuso, A. J.; Swern, D. *Synthesis* **1981**, 165.

(11) (a) Heathcock, C. H.; Hagen, J. P.; Jarvi, E. T.; Pirrung, M. C.; Young, S. D. *J. Am. Chem. Soc.* **1981**, *103*, 4972. (b) Heathcock, C. H.; Pirrung, M. C.; Young, S. D.; Hagen, J. P.; Jarvi, E. T.; Badertscher, U.; Märki, H.-P.; Montgomery, S. H. *J. Am. Chem. Soc.* **1984**, *106*, 8161. (c) Heathcock, C. H.; Young, S. D.; Hagen, J. P.; Pilli, R.; Badertscher, U. *J. Org. Chem.* **1985**, *50*, 2095. (d) Hoagland, S.; Morita, Y.; Bai, D. L.; Märki, H.-P.; Kees, K.; Brown, L.; Heathcock, C. H. *J. Org. Chem.* **1988**, *53*, 4730.


(12) Lactate aryl ester **12** was prepared from methyl *O*-methoxymethyl lactate by a three step sequence of ester hydrolysis (LiOH, MeOH/H₂O), acid chloride formation ((COCl)₂, CH₂Cl₂), and condensation with lithium 2,6-di-*tert*-butyl-4-methylphenoxide (THF).¹¹

(13) The stereochemical proof of aldol products **13** and **14** is presented in the Supporting Information.



Subsequent DDQ deprotection of the PMB ether afforded alcohol **18** in excellent yield. Treatment of **18** with excess Me₂BBr in the presence of 2,6-di-*tert*-butyl-4-methylpyridine induced a rapid intramolecular transketalization and provided the desired seven-membered acetal **19** in 91% yield.¹⁴


Although the transketalization strategy proved quite effective, the difficulties encountered in attempted protection of **17** as a TBS ether prompted a search for a more suitable protecting group. Reasoning that the low yield was a result of the steric congestion about the C(7) alcohol, we turned to the sterically smaller TES ether. Accordingly, we were quite pleased to find that treatment of **17** with 4 equiv of commercial grade TESOTf in the presence of 2,6-lutidine (8 equiv) in CH₂Cl₂ not only led to silylation of the alcohol, but also initiated a remarkable sequence of events involving debenzoylation of the PMB ether and transketalization of the MOM ether to afford the seven-membered acetal **20** in 78% yield (Scheme 3)! Further investigation revealed that TES



ether **21** was formed immediately along with the minor byproducts **23** and **24** upon addition of 1 equiv of TESOTf to **17**. Further treatment with 3 equiv of TESOTf resulted in the slower conversion of **21** to acetal **20**. The use of fewer equivalents of additional TESOTf resulted in slower conversion rates and/or incomplete reaction. We believe that the methoxymethyl ether is activated by traces of TfOH in the commercial TESOTf, as use of distilled TESOTf again gave much slower conversion rates. Intramolecular interception of the activated MOM ether by the PMB ether oxygen gives acetal **20** after debenzoylation of the oxonium ion **24**.

With an efficient synthesis of **20** in hand, we turned to the elaboration of the trisubstituted vinyl iodide (Scheme 4). Accordingly, the vinyl group of **20** was converted into the corresponding alkyne **26** by oxidative cleavage to aldehyde **25**, Gilbert–Seyferth homologation,¹⁵ and DIBAL–H reduc-

(14) (a) Gustin, D. J.; VanNieuwenhze, M. S.; Roush, W. R. *Tetrahedron Lett.* **1995**, *36*, 3447. (b) Guidon, Y.; Yoakim, C.; Morton, H. E. *J. Org. Chem.* **1984**, *49*, 3912.



tion of the pivalate ester. However, the carbalumination¹⁶ of **26** proved extremely sluggish, proceeding only after addition of a large excess of Me₃Al in refluxing dichloroethane over 18 h. The subsequent iodination of the vinylalane intermediate provided an inseparable 1:1 mixture of the vinyl iodide **27** and disubstituted alkene **28** in low mass recovery. Following Swern oxidation of the alcohol,¹⁰ treatment of the resulting aldehyde with Ph₃P=C(Me)CO₂Me, and HPLC purification, the targeted vinyl iodide **29** was isolated in 16% overall yield from **26**.

Since introduction of the trisubstituted vinyl iodide through a Negishi carbalumination was very inefficient, we redesigned the synthesis to allow for the introduction of the trisubstituted olefin at an earlier stage. Since we anticipated that a vinyl iodide would not be compatible with the LiAlH₄ reduction step (e.g., conversion of **13** to **15**), we chose to use a vinyl silane as a vinyl iodide surrogate (Scheme 5). Using the conditions of Danheiser and co-workers,¹⁷ treatment of TMS ether **30** with *t*-BuLi initiated a retro-Brook 1,2-silyl migration to give the corresponding α-silyllithium alkoxide which was trapped with Ac₂O to afford acetate **31**.¹⁸ Treatment of **31** with TBSOTf and Et₃N in CH₂Cl₂ over 3 days promoted an Ireland-ester Claisen rearrangement¹⁹ which gave vinyl silane **32** as a single *trans*-olefin isomer. Cleavage of the silyl ester with TMSOK gave the potassium carboxylate salt,²⁰ which was treated in situ with PivCl to afford the mixed anhydride. Addition of the lithiated oxazolidinone then provided the *N*-acyl oxazolidinone **33** in 54% overall yield from **30**. Asymmetric aldol coupling of **33** with hexanal gave **34** in excellent yield and diastereoselectivity.

(15) (a) Gilbert, J. C.; Weerasooriya, U. *J. Org. Chem.* **1979**, *44*, 4997. (b) Seyfert, D.; Marmor, R. S.; Hilbert, P. *J. Org. Chem.* **1971**, *36*, 1379.

(16) Negishi, E.-I.; Van Horn, D. E.; Yoshida, T. *J. Am. Chem. Soc.* **1985**, *107*, 6639.


(17) Danheiser, R. L.; Fink, D. M.; Okano, K.; Tsai, Y.-M.; Szczepanski, S. W. *J. Org. Chem.* **1985**, *50*, 5393.

(18) Calter, P.; Evans, D. A. Ph.D. Thesis, Harvard University, 1993.

(19) Ireland, R. E.; Varney, M. D. *J. Am. Chem. Soc.* **1984**, *106*, 3668.

(20) Laganis, E. D.; Chenard, B. L. *Tetrahedron Lett.* **1984**, *25*, 5831.

Scheme 5



The oxazolidinone auxiliary was removed by NaBH₄ reduction to provide the corresponding diol in 78% yield.²¹ Formation of the *p*-methoxybenzylidene acetal followed by DIBAL-H reductive cleavage gave the PMB ether **35** in excellent yield. Swern oxidation of the primary alcohol **35** and condensation of the resulting aldehyde with the lithium enolate of aryl lactate ester **12** provided an 82:18 mixture of aldols with the desired all-*syn* diastereomer **36** predominating (79% yield). In this case, the diastereomers were separable

(21) Prashad, M.; Har, D.; Kim, H.-Y.; Repic, O. *Tetrahedron Lett.* **1998**, *39*, 7067.

by HPLC. LiAlH₄ reduction of **36** gave the corresponding diol in near quantitative yield. Attempts to protect the primary alcohol as a pivalate ester were unsuccessful. However, the diol could be selectively converted to the monoacetate **37** by treatment with Ac₂O in pyridine and CH₂Cl₂. Treatment of **37** with excess TESOTf and 2,6-lutidine using the procedure developed for the conversion of **17** to **20** afforded the seven-membered acetal **38** in 42% yield.²²

The vinyl silane was converted to the vinyl iodide (89% yield) as a single olefin isomer by treatment of **38** with *N*-iodosuccinimide. DIBAL-H reductive deprotection of the acetate ester (96% yield) followed by Swern oxidation of the resulting alcohol (88% yield) provided the sterically hindered aldehyde **39** in very good overall yield. Wittig olefination of **39** with Ph₃P=C(Me)CO₂Me in toluene at reflux gave the corresponding enoate in 91% yield. DIBAL-H reduction of the ester to the allylic alcohol (91% yield) followed by Swern oxidation (84% yield) gave the unsaturated aldehyde **40** in very good yield. Finally, the remaining olefin was introduced by condensation of aldehyde **40** with Ph₃P=CHCO₂Me in warm benzene to provide the *trans,trans*-dienoate methyl ester **6** in 91% yield as a single olefin isomer.

In conclusion, we have developed an efficient, stereo-selective synthesis of the C(1)–C(11) fragment of formamycin. Further progress toward completion of a total synthesis of this interesting natural product will be reported in due course.

Acknowledgment. This work was supported by the National Institutes of Health (GM 38436). N.A.P. gratefully acknowledges the NIH for a postdoctoral fellowship (GM 20278).

Supporting Information Available: References to syntheses of other members of the plecomacrolide family, stereochemical assignments of aldols **13** and **14**, and experimental procedures for synthesis of **20**, **30–39**, and **6**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL0069610

(22) An additional 18% of material was recovered in form of four minor byproducts **43–46**. Interestingly, products containing five membered acetals, analogous to **23** and **24** (Scheme 3), were not observed.

